Drug Recalls Archives - Page 2 of 42

Johnson & Johnson Baby Powder Recalled Due to Asbestos Contamination

October 22, 2019 By Sandra Dalton Leave a Comment

On Friday, October 18, 2019, Johnson & Johnson (J&J) announced a recall of 33,000 bottles of its baby powder, due to contamination with asbestos. The recall applies to one lot, lot #22318RB, which was distributed in 2018. If you have a bottle of Johnson’s Baby Powder from this lot, you are advised to discontinue use and contact the company … [Read more...]

Heartburn Drug Contaminated with NDMA

September 23, 2019 By Lynn Fugaro Leave a Comment

The Food and Drug Administration (FDA) has announced that low levels of a potentially dangerous contaminant have been found in Zantac heartburn medication, both the prescription and over-the-counter version of the popular drug taken to treat stomach acid and ulcers. FDA officials report that while the amount of NDMA found in the drug “barely … [Read more...]

New Research May Show Link Between Talcum Powder and Cancer

July 11, 2019 By Lynn Fugaro Leave a Comment

For years, Johnson & Johnson has been plagued with allegations that its famous baby powder causes ovarian cancer when it’s used in the genital area over long periods of time by women. While Johnson & Johnson has insisted its product is safe, juries across the United States have disagreed and have awarded large sums of money to female … [Read more...]

Dangerous Drug Lawsuit: Truvada

July 8, 2019 By Lynn Fugaro Leave a Comment

Truvada, marketed by the manufacturer Gilead, is the most popular and oft-prescribed TDF drug designed to treat and prevent human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). A combination of the chemicals emtricitabine and tenofovir disoproxil fumarate (TDF), Truvada prevents HIV cells from multiplying once those … [Read more...]

Xeljanz May Cause Blood Clots and Death According to Safety Study

June 13, 2019 By Sandra Dalton Leave a Comment

On February 29, 2019, the U.S. Food and Drug Administration (FDA) issued a safety communication warning the public about an increased risk of blood clots and death in patients with rheumatoid arthritis taking a high dose of Xeljanz (tofacitinib). The warning was prompted by a mandatory post-marketing safety trial of the drug. The trial is still … [Read more...]